Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | SAT1 | P21673 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5932913 | 0.97 | CYP2C19 (0.53) | CYP2C19MEN1KMT2AGLATSHR | |
| SCHEMBL3797316 | 0.97 | CYP2C19 (0.45) | CYP2C19MEN1KMT2AGLATSHR | |
| SCHEMBL26465383 | 0.94 | CYP2C19 (0.50) | CYP2C19MEN1KMT2AGLATSHR | |
| SCHEMBL1755888 | 0.91 | — | — | |
| SCHEMBL24673833 | 0.89 | CYP2C19 (0.46) | CYP2C19MEN1KMT2AGLATSHR | |
| SCHEMBL21657595 | 0.89 | KDM4E (0.40) | CYP2C19MEN1KMT2AGLATSHR | |
| SCHEMBL21106559 | 0.89 | KDM4E (0.40) | CYP2C19MEN1KMT2AGLATSHR | |
| SCHEMBL22856109 | 0.89 | TSHR (0.43) | CYP2C19MEN1KMT2AGLATSHR | |
| SCHEMBL16394016 | 0.89 | KDM4E (0.40) | CYP2C19MEN1KMT2AGLATSHR | |
| SCHEMBL7475456 | 0.89 | KDM4E (0.40) | CYP2C19MEN1KMT2AGLATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109666123-A | A kind of fiberglass reinforced honeycomb sandwich board urethane composition and its application method | 黎明化工研究设计院有限责任公司 | 2019-04-23 | — | — | CN | claimed |
| CN-105384895-B | Polyurethane composition polyethers, hard polyurethane foam and its preparation method and application | 上海东大聚氨酯有限公司 | 2018-05-25 | — | — | CN | claimed |
| CN-105131237-B | The preparation method of full water foamed plant oil base RPUF | 盐城工学院 | 2017-12-22 | — | — | CN | claimed |
| CN-120119482-A | High-dye-utilization-rate ink for ink-jet printing and preparation method thereof | 青岛大学 | 2025-06-10 | — | — | CN | disclosed |
| WO-2024044549-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2022125800-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125790-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20220162156-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | Cellix Bio Provate Limited (IN) | 2022-05-26 | — | — | US | disclosed |
| WO-2021133920-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20150175735-A1 | New Non-Emissive Amine Composition For Improved System Shelf Life Stability | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-9062009-B2 | Macrocyclic compounds and metal complexes for bioimaging and biomedical applications | NATIONAL YANG MING UNIVERSITY (TW) | 2015-06-23 | — | — | US | disclosed |
| US-20140187527-A1 | Macrocyclic Compounds And Metal Complexes For Bioimaging And Biomedical Applications | NATIONAL YANG MING UNIVERSITY (TW) | 2014-07-03 | — | — | US | disclosed |
| CN-101001615-B | Drug delivery product and method | NEXMED HOLDINGS INC | 2012-07-04 | — | — | CN | disclosed |
| CN-101883605-A | Methods and devices for local therapeutic agent delivery to heart valves | BOSTON SCIENT SCIMED INC | 2010-11-10 | — | — | CN | disclosed |
| CN-101001615-A | Drug delivery product and method | NEXMED HOLDINGS INC (US) | 2007-07-18 | — | — | CN | disclosed |
| EP-1041094-B1 | Water-based coating composition | NIPPON MITSUBISHI OIL CORP (JP) | 2005-06-08 | — | — | EP | disclosed |
| US-6368521-B1 | ULTRAVIOLET ABSORPTION ACRYLIC POLYMER | NIPPON MITSUBISHI OIL CORPORATION (JP) | 2002-04-09 | — | — | US | disclosed |
| EP-1041094-A1 | Water-based coating composition | Nippon Mitsubishi Oil Corporation (JP) | 2000-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162156-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | SI, SLC10A2, F5 | CYP2C19 17/4885MEN1 3871/4885KMT2A 4756/4885 |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | CYP2C19 3642/4885MEN1 2643/4885KMT2A 1723/4885 |
| US-20140187527-A1 | Macrocyclic Compounds And Metal Complexes For Bioimaging And Biomedical Applications | DNASE1L3, DNASE1, SNRPA | CYP2C19 4593/4885MEN1 576/4885KMT2A 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.